CN100406069C - A kind of CaO-P2O5-Na2O-TiO2-ZrO2 biological glass ceramics and its preparation method - Google Patents
A kind of CaO-P2O5-Na2O-TiO2-ZrO2 biological glass ceramics and its preparation method Download PDFInfo
- Publication number
- CN100406069C CN100406069C CNB2005100472836A CN200510047283A CN100406069C CN 100406069 C CN100406069 C CN 100406069C CN B2005100472836 A CNB2005100472836 A CN B2005100472836A CN 200510047283 A CN200510047283 A CN 200510047283A CN 100406069 C CN100406069 C CN 100406069C
- Authority
- CN
- China
- Prior art keywords
- glass
- zro
- cao
- tio
- ceramics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002241 glass-ceramic Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- MCMNRKCIXSYSNV-UHFFFAOYSA-N ZrO2 Inorganic materials O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 title description 7
- 239000011521 glass Substances 0.000 claims abstract description 50
- 229910010413 TiO 2 Inorganic materials 0.000 claims abstract description 35
- 239000000919 ceramic Substances 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 239000010935 stainless steel Substances 0.000 claims abstract description 8
- 229910001220 stainless steel Inorganic materials 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000002245 particle Substances 0.000 claims description 8
- 239000002002 slurry Substances 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 5
- 238000003825 pressing Methods 0.000 claims description 5
- 238000005245 sintering Methods 0.000 claims description 4
- 238000004080 punching Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 239000010839 body fluid Substances 0.000 abstract description 16
- 210000001124 body fluid Anatomy 0.000 abstract description 16
- 238000002791 soaking Methods 0.000 abstract description 15
- 239000000463 material Substances 0.000 abstract description 14
- 210000000988 bone and bone Anatomy 0.000 abstract description 12
- 229910052588 hydroxylapatite Inorganic materials 0.000 abstract description 12
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 abstract description 12
- 230000004071 biological effect Effects 0.000 abstract description 8
- 229910004298 SiO 2 Inorganic materials 0.000 abstract description 7
- 210000001519 tissue Anatomy 0.000 abstract description 7
- 238000001035 drying Methods 0.000 abstract description 5
- 239000007943 implant Substances 0.000 abstract description 5
- 229910052751 metal Inorganic materials 0.000 abstract description 4
- 239000002184 metal Substances 0.000 abstract description 4
- 230000011164 ossification Effects 0.000 abstract description 3
- 231100000701 toxic element Toxicity 0.000 abstract description 2
- 239000011575 calcium Substances 0.000 description 9
- 239000005312 bioglass Substances 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000012876 topography Methods 0.000 description 4
- 239000005313 bioactive glass Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 239000012890 simulated body fluid Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 239000003484 crystal nucleating agent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000004820 osteoconduction Effects 0.000 description 1
- 238000013001 point bending Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- -1 silicon dioxide calcium phosphorus Chemical compound 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C10/00—Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/12—Silica-free oxide glass compositions
- C03C3/16—Silica-free oxide glass compositions containing phosphorus
- C03C3/21—Silica-free oxide glass compositions containing phosphorus containing titanium, zirconium, vanadium, tungsten or molybdenum
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C4/00—Compositions for glass with special properties
- C03C4/0007—Compositions for glass with special properties for biologically-compatible glass
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Geochemistry & Mineralogy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Ceramic Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Glass Compositions (AREA)
Abstract
本发明涉及一种CaO-P2O5-Na2O-TiO2-ZrO2生物玻璃陶瓷及其制备方法,玻璃陶瓷中,CaO和P2O5总含量在80~90mol%,Na2O的含量在4~7mol%,其余为TiO2和ZrO2。其制备过程如下:将原料混合均匀,经干燥后加热熔融,然后取出倒在不锈钢钢板上冲压制备玻璃;将冲压所得玻璃球磨成粉后,冷压成块并烧结获得玻璃陶瓷。该玻璃陶瓷不含SiO2,无有毒元素,具有良好的生物活性,在模拟人体体液中浸泡4天有一层致密均匀的羟基磷灰石生成;具有较高强度(大于90MPa),可以进行切削,便于加工;具有较高的Ca/P比以及和人体硬组织相似的成分,可以作为人体硬组织替代和修复材料。该生物玻璃陶瓷具有生物玻璃陶瓷的共性,和金属植入物相比可望获得更快的成骨能力和更高的骨键合强度。The invention relates to a CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 biological glass ceramic and a preparation method thereof. In the glass ceramic, the total content of CaO and P 2 O 5 is 80-90 mol%, and the Na 2 O The content of TiO 2 and ZrO 2 is 4~7mol%. The preparation process is as follows: mix the raw materials evenly, heat and melt them after drying, then take them out and pour them on the stainless steel plate to punch them to make glass; grind the punched glass balls into powder, cold press them into blocks and sinter them to obtain glass ceramics. The glass-ceramic does not contain SiO 2 , has no toxic elements, and has good biological activity. After soaking in simulated human body fluid for 4 days, a layer of dense and uniform hydroxyapatite is formed; it has high strength (greater than 90MPa), and can be cut. Easy to process; with high Ca/P ratio and composition similar to human hard tissue, it can be used as a replacement and repair material for human hard tissue. The bioglass-ceramic has the generality of bioglass-ceramics, and it is expected to obtain faster bone formation and higher bone bonding strength compared with metal implants.
Description
技术领域:Technical field:
本发明涉及玻璃陶瓷领域,特别是涉及临床医学应用的具有高强度和高生物活性的CaO-P2O5-Na2O-TiO2-ZrO2生物玻璃陶瓷及其制备方法。The invention relates to the field of glass ceramics, in particular to CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 biological glass ceramics with high strength and high biological activity for clinical medicine application and a preparation method thereof.
背景技术:Background technique:
人体硬组织修复与重建材料是生物医学材料中发展最早、最成熟的领域。迄今为止,用于硬组织修复与替换的材料有金属与合金、生物玻璃陶瓷、聚合物、复合材料及人和动物的骨骼衍生物等,见参考文献[1]:俞耀庭.生物医用材料.天津:天津大学出版社,2000:116。生物活性玻璃陶瓷是一类能与生物软组织或骨组织键合的生物材料,具有金属、高分子及生物惰性材料不可比拟的优势。因此,人们对这类新型材料产生了浓厚的兴趣,并研制出多种生物活性玻璃陶瓷,例如:生物玻璃(Na2O-CaO-SiO2-P2O5系)、Ceravital微晶玻璃(Na2O-K2O-MgO-CaO-P2O5-SiO2系)、A-W生物玻璃陶瓷(MgO-CaO-SiO2-P2O5系)、羟基磷灰石生物活性陶瓷(HA,组成为:Ca10(PO4)6(OH)2)等等,见参考文献[2]和[3],参考文献[2]:Larry L.Hench.Bioceramics.J.Am.Ceram.Soc.1998,81[7]:1705-1728;参考文献[3]:杨为中,周大利,尹光福和郑昌琼.生物医学工程学杂志.2003,20(3):541-545。和其它生物惰性材料相比,生物玻璃陶瓷具有更好的生物相容性、更高的骨键合强度和更快的成骨能力,见参考文献[4]:李玉宝.生物医学材料.北京:化学工业出版社,2003:82。但是大多数生物活性玻璃都含有大量的SiO2,而Nagase et al.发现在实验老鼠腹腔注射含二氧化硅钙磷玻璃的当量盐水时老鼠死亡,而不含二氧化硅时则不显示毒性,见参考文献[5]:Nagase M,Abe Y,Chigira M and Udagawa E.Toxicity of silica-containing calciumposphate glasses demonstrated in mice.Biomaterials.1992,13:172-175。Human hard tissue repair and reconstruction materials are the earliest and most mature field of biomedical materials. So far, materials used for hard tissue repair and replacement include metals and alloys, bioglass ceramics, polymers, composite materials, and bone derivatives of humans and animals, etc., see reference [1]: Yu Yaoting. Biomedical Materials. Tianjin : Tianjin University Press, 2000: 116. Bioactive glass ceramics are a class of biomaterials that can bond with biological soft tissue or bone tissue, and have incomparable advantages over metals, polymers, and bioinert materials. As a result, there has been strong interest in this class of novel materials, and a variety of bioactive glass-ceramics have been developed, such as: Bioglass (Na 2 O-CaO-SiO 2 -P 2 O 5 series), Ceravital glass ceramics (Na 2 OK 2 O-MgO-CaO-P 2 O5-SiO 2 series), AW bioglass ceramics (MgO- CaO-SiO 2 -P 2 O 5 series), hydroxyapatite bioactive ceramics (HA, composed of: Ca 10 (PO 4 ) 6 (OH) 2 ), etc., see references [2] and [3] , Reference [2]: Larry L.Hench.Bioceramics.J.Am.Ceram.Soc.1998, 81[7]: 1705-1728; Reference [3]: Yang Weizhong, Zhou Dali, Yin Guangfu and Zheng Changqiong. Biomedicine Journal of Engineering. 2003, 20(3): 541-545. Compared with other biologically inert materials, bioglass ceramics have better biocompatibility, higher bone bonding strength and faster bone formation ability, see reference [4]: Li Yubao. Biomedical Materials. Beijing: Chemical Industry Press, 2003: 82. However, most bioactive glasses contain a large amount of SiO 2 , and Nagase et al. found that mice died when intraperitoneally injected with the equivalent saline containing silicon dioxide calcium phosphorus glass, but did not show toxicity when there was no silicon dioxide, See reference [5]: Nagase M, Abe Y, Chigira M and Udagawa E. Toxicity of silica-containing calcium phosphate glasses demonstrated in mice. Biomaterials. 1992, 13: 172-175.
生物玻璃陶瓷在临床上作为骨替代材料是通过骨传导途径完成的。由于其良好的生物相容性,植入机体后不引起明显反应,植入物周围宿主骨痂可通过爬行面汇合,并将植入物包裹,使之起到充填和连接骨缺损的作用。但是其较低的韧性限制了它的推广应用。氧化锆陶瓷是新近发展起来的仅次于氧化铝的一种很重要的结构陶瓷。由于它的良好性能,如高硬度、高强度和较高的断裂韧性,因而越来越受到人们的重视,见参考文献[6]:刘维良.先进陶瓷工艺学.武汉:武汉理工大学出版社.2004:176-180。氧化锆很早就作为晶核剂而加入到玻璃陶瓷中。在玻璃成份中加入氧化锆微粒,可使玻璃断裂强度从2MPa提高到3MPa,见参考文献[7]:汤继文、张玉德和刘春梅.生物活性玻璃陶瓷人工骨材料的研究进展.山东医药.1997,37[5]:45-50。CaO-P2O5系玻璃陶瓷是新近发展起来的一种新型生物玻璃陶瓷,该系陶瓷的成份与人体骨组织接近,具有良好的生物活性并且无毒,见参考文献[8]:Kasuga T and Abe Y.Calcium phosphate invert glasses with soda andtitania.J.Non-cryst.Solids.1999,243:70-74。本发明在CaO-P2O5系玻璃陶瓷基础上,引入ZrO2,形成CaO-P2O5-Na2O-TiO2-ZrO2系玻璃陶瓷。它是一种不含SiO2的生物玻璃,具有较高的Ca/P比以及和人体硬组织相似的成份,具有较高的断裂强度和生物活性,更适合做人体植入材料。Bioglass-ceramic is clinically used as a bone substitute material through osteoconduction. Due to its good biocompatibility, it does not cause obvious reactions after being implanted in the body. The host callus around the implant can converge through the crawling surface and wrap the implant so that it can fill and connect the bone defect. But its low toughness limits its popularization and application. Zirconia ceramics are a newly developed very important structural ceramics second only to alumina. Because of its good properties, such as high hardness, high strength and high fracture toughness, it has attracted more and more attention. See reference [6]: Liu Weiliang. Advanced Ceramic Technology. Wuhan: Wuhan University of Technology Press. 2004: 176-180. Zirconia has long been added to glass ceramics as a crystal nucleating agent. Adding zirconia particles to the glass composition can increase the breaking strength of the glass from 2MPa to 3MPa, see reference [7]: Tang Jiwen, Zhang Yude and Liu Chunmei. Research progress of bioactive glass ceramic artificial bone materials. Shandong Medicine. 1997, 37 [5]: 45-50. CaO-P 2 O 5 series glass ceramics is a new type of biological glass ceramics recently developed. The composition of this series of ceramics is close to that of human bone tissue. It has good biological activity and is non-toxic. See reference [8]: Kasuga T and Abe Y. Calcium phosphate invert glasses with soda and titania. J. Non-cryst. Solids. 1999, 243:70-74. The present invention introduces ZrO 2 on the basis of CaO-P 2 O 5 series glass ceramics to form CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 series glass ceramics. It is a kind of bioglass without SiO 2 , has a high Ca/P ratio and a composition similar to that of human hard tissue, has high breaking strength and biological activity, and is more suitable as a human implant material.
发明内容 Contents of the invention
本发明的目的是提供一种新型CaO-P2O5-Na2O-TiO2-ZrO2生物玻璃陶瓷及其制备方法。该玻璃陶瓷具有良好的生物活性、较高硬度、强度和可切削性,具有和人体硬组织相似的成份,可以作为人体硬组织替代和修复材料。The object of the present invention is to provide a novel CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 biological glass ceramic and its preparation method. The glass-ceramic has good biological activity, relatively high hardness, strength and machinability, has a composition similar to that of human hard tissue, and can be used as a replacement and repair material for human hard tissue.
本发明的技术方案是:Technical scheme of the present invention is:
本发明提供一种CaO-P2O5-Na2O-TiO2-ZrO2生物玻璃陶瓷,CaO和P2O5总含量在80~90mol%,Na2O的含量在4~7mol%,其余为TiO2和ZrO2。The invention provides a CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 biological glass ceramic, the total content of CaO and P 2 O 5 is 80-90 mol%, the content of Na 2 O is 4-7 mol%, The rest are TiO 2 and ZrO 2 .
本发明提供的CaO-P2O5-Na2O-TiO2-ZrO2生物玻璃陶瓷,所述玻璃陶瓷中,Ca与P摩尔比为0.5~1.5。In the CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 biological glass ceramics provided by the invention, in the glass ceramics, the molar ratio of Ca to P is 0.5-1.5.
本发明提供的CaO-P2O5-Na2O-TiO2-ZrO2生物玻璃陶瓷,所述玻璃陶瓷中,ZrO2的含量在0.5~10mol%。In the CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 biological glass ceramics provided by the invention, the content of ZrO 2 in the glass ceramics is 0.5-10 mol%.
本发明提供的的CaO-P2O5-Na2O-TiO2-ZrO2生物玻璃陶瓷的制备方法,包括玻璃的制备和陶瓷的制备,具体步骤如下:The preparation method of CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 biological glass ceramics provided by the present invention includes the preparation of glass and the preparation of ceramics, and the specific steps are as follows:
(1)玻璃的制备(1) Preparation of glass
以CaCO3,Na2CO3,TiO2,ZrO2和H3PO4为原料,按所述成份将原料混合均匀,配制玻璃浆液,经干燥后捣碎加热熔融,然后取出倒在不锈钢钢板上冲压;Using CaCO 3 , Na 2 CO 3 , TiO 2 , ZrO 2 and H 3 PO 4 as raw materials, mix the raw materials evenly according to the stated ingredients, prepare glass slurry, grind it after drying, heat and melt it, then take it out and pour it on the stainless steel plate stamping;
(2)陶瓷的制备(2) Preparation of ceramics
将冲压所得玻璃球磨成粉后,冷压成块并烧结。The punched glass balls are ground into powder, cold pressed into blocks and sintered.
所述步骤1中,玻璃浆液经干燥后捣碎,捣碎后粉的粒度为5~10μm。In the step 1, the glass slurry is dried and crushed, and the particle size of the crushed powder is 5-10 μm.
所述步骤1中,在1300~1400℃下加热熔融、保温时间0.5~1小时后,立即取出倒在不锈钢钢板上冲压得玻璃。In the step 1, heat and melt at 1300-1400° C., hold the temperature for 0.5-1 hour, take out immediately and pour it on the stainless steel plate to punch the glass.
所述步骤2中,将冲压所得的玻璃球磨成粉,粉的粒度为1~10μm。In the step 2, the glass ball obtained by punching is ground into powder, and the particle size of the powder is 1-10 μm.
所述步骤2中,冷压压力为80~150MPa,玻璃粉烧结温度为800~850℃,时间为1~2/小时。In the step 2, the cold pressing pressure is 80-150 MPa, the glass powder sintering temperature is 800-850° C., and the time is 1-2/hour.
本发明提供的CaO-P2O5-Na2O-TiO2-ZrO2生物玻璃陶瓷的制备方法,所述玻璃所用原料为化学试剂:CaCO3,Na2CO3,TiO2,ZrO2和H3PO4(液体,重量百分比为85%),均为分析纯。In the preparation method of CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 biological glass ceramics provided by the present invention, the raw materials used in the glass are chemical reagents: CaCO 3 , Na 2 CO 3 , TiO 2 , ZrO 2 and H 3 PO 4 (liquid, 85% by weight), all of which are analytically pure.
本发明提供的CaO-P2O5-Na2O-TiO2-ZrO2生物玻璃陶瓷的制备方法,在模拟人体体液中浸泡4-7天表面有均匀致密的羟基磷灰石生成,表面活性高。In the preparation method of CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 biological glass ceramics provided by the present invention, uniform and dense hydroxyapatite is formed on the surface after soaking in simulated human body fluid for 4-7 days, and the surface activity high.
本发明提供的CaO-P2O5-Na2O-TiO2-ZrO2生物玻璃陶瓷的制备方法,所制得的陶瓷抗弯强度大于90MPa,优于生物玻璃。According to the preparation method of CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 biological glass ceramics provided by the present invention, the bending strength of the prepared ceramics is greater than 90MPa, which is better than bioglass.
本发明提供的CaO-P2O5-Na2O-TiO2-ZrO2系玻璃陶瓷具有良好的生物活性,在模拟人体体液(SBF)中浸泡4-7天后表面有羟基磷灰石生成。其良好的生物活性和力学性质不仅可以作为牙齿、颌面骨及中耳骨亦可作为人工椎体、椎间盘和髂嵴等医用材料。The CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 series glass ceramics provided by the invention have good biological activity, and hydroxyapatite is formed on the surface after soaking in simulated human body fluid (SBF) for 4-7 days. Its good biological activity and mechanical properties can not only be used as teeth, maxillofacial bone and middle ear bone, but also as medical materials such as artificial vertebral body, intervertebral disc and iliac crest.
本发明的有益效果是:The beneficial effects of the present invention are:
本发明玻璃陶瓷不含SiO2,无有毒元素,具有良好的生物活性,在模拟人体体液中浸泡4天有一层致密均匀的羟基磷灰石生成;具有较高强度(大于90MPa),可以进行切削,便于加工;具有较高的Ca/P比以及和人体硬组织相似的成份,可以作为人体硬组织替代和修复材料。该生物玻璃陶瓷具有生物玻璃陶瓷的共性,和金属植入物相比可望获得更快的成骨能力和更高的骨键合强度。The glass-ceramic of the present invention does not contain SiO 2 , has no toxic elements, and has good biological activity. After soaking in simulated human body fluid for 4 days, a layer of dense and uniform hydroxyapatite is formed; it has high strength (greater than 90MPa), and can be cut , easy to process; with a high Ca/P ratio and similar composition to human hard tissue, it can be used as a replacement and repair material for human hard tissue. The bioglass-ceramic has the generality of bioglass-ceramics, and it is expected to obtain faster bone formation and higher bone bonding strength compared with metal implants.
附图说明: Description of drawings:
图1快速冲压所得CaO-P2O5-Na2O-TiO2-ZrO2玻璃;Figure 1 CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 glass obtained by rapid stamping;
图2快速冲压所得60CaO30P2O54Na2O3TiO23ZrO2玻璃经1000#砂纸打磨后形貌图;Fig. 2 The morphology of 60CaO30P 2 O 5 4Na 2 O3TiO 2 3ZrO 2 glass obtained by rapid stamping after grinding with 1000# sandpaper;
图360CaO30P2O54Na2O3TiO23ZrO2玻璃在模拟人体体液中浸泡4天后的形貌图;Figure 360 Topography of CaO30P 2 O 5 4Na 2 O3TiO 2 3ZrO 2 glass soaked in simulated human body fluid for 4 days;
图460CaO30P2O54Na2O3TiO23ZrO2玻璃在模拟人体体液中浸泡4天后的形貌图的放大照片;Figure 460 The enlarged photo of the topography of CaO30P2O54Na2O3TiO23ZrO2 glass soaked in simulated human body fluid for 4 days;
图560CaO30P2O55Na2O3TiO22ZrO2玻璃在模拟人体体液中浸泡7天后的形貌图;Figure 560 Topography of CaO30P 2 O 5 5Na 2 O3TiO 2 2ZrO 2 glass soaked in simulated human body fluid for 7 days;
图660CaO30P2O55Na2O3TiO22ZrO2玻璃模拟人体体液中浸泡7天后的X-射线衍射图谱; Fig . 660 CaO30P2O55Na2O3TiO22ZrO2The X -ray diffraction spectrum of glass simulated human body fluid soaked in 7 days;
图7CaO-P2O5-Na2O-TiO2-ZrO2玻璃粉碎冷压烧结后所得玻璃陶瓷;Fig. 7 Glass ceramics obtained after CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 glass pulverization, cold pressing and sintering;
图860CaO30P2O55Na2O3TiO22ZrO2玻璃陶瓷的成份衍射图谱;Figure 860CaO30P 2 O 5 5Na 2 O3TiO 2 2ZrO 2 The composition diffraction pattern of glass ceramics;
图960CaO30P2O54Na2O3TiO23ZrO2玻璃陶瓷在模拟人体体液中浸泡7天后的形貌图。Fig. 960 Topography of CaO30P 2 O 5 4Na 2 O3TiO 2 3ZrO 2 glass-ceramics soaked in simulated human body fluid for 7 days.
具体实施方式: Detailed ways:
实施例1Example 1
用分析纯CaCO3,Na2CO3,TiO2,ZrO2和H3PO4(85%)为原料配制按表1所述成份玻璃浆液,用电动搅拌机将原料混合均匀,然后置于50℃干燥箱内干燥24h。将干燥后原料捣成粉末(粒度为5-10μm)置于铂金坩埚内在1350℃保温0.5h,立即取出倒在不锈钢钢板上并快速冲压即得玻璃。所得玻璃宏观形貌见图1。Use analytically pure CaCO 3 , Na 2 CO 3 , TiO 2 , ZrO 2 and H 3 PO 4 (85%) as raw materials to prepare a glass slurry with the ingredients described in Table 1, mix the raw materials evenly with an electric mixer, and then place at 50°C Dry in a drying oven for 24 hours. Pound the dried raw material into powder (with a particle size of 5-10 μm) and place it in a platinum crucible at 1350°C for 0.5h, take it out immediately, pour it on a stainless steel plate, and press it quickly to obtain glass. The macroscopic morphology of the obtained glass is shown in Fig. 1 .
表1CaO-P2O5-Na2O-TiO2-ZrO2玻璃成份Table 1CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 glass components
实施例2Example 2
将冲压所得60CaO30P2O54Na2O3TiO23ZrO2玻璃在模拟人体体液(表2)中37℃浸泡4天后,表面有一层致密均匀的羟基磷灰石生成。其浸泡前微观形貌如图2所示,浸泡后微观形貌如图3、图4所示。After soaking the punched 60CaO30P 2 O 5 4Na 2 O3TiO 2 3ZrO 2 glass in simulated human body fluid (Table 2) at 37°C for 4 days, a layer of dense and uniform hydroxyapatite formed on the surface. The microscopic morphology before soaking is shown in Figure 2, and the microscopic morphology after soaking is shown in Figure 3 and Figure 4.
表2人体中的血浆和模拟人体体液(SBF)中的离子浓度(mM)Table 2 Ion concentrations (mM) in plasma and simulated body fluid (SBF) in the human body
实施例3Example 3
将冲压所得60CaO30P2O55Na2O3TiO22ZrO2玻璃在37℃模拟人体体液(表2)中浸泡7天后,表面有一层致密均匀的羟基磷灰石生成。浸泡后微观形貌如图5所示,其X-射线衍射图谱如图6所示。After soaking the punched 60CaO30P 2 O 5 5Na 2 O3TiO 2 2ZrO 2 glass in simulated human body fluid (Table 2) at 37°C for 7 days, a layer of dense and uniform hydroxyapatite was formed on the surface. The microscopic morphology after soaking is shown in Figure 5, and its X-ray diffraction pattern is shown in Figure 6.
实施例4Example 4
将冲压所得玻璃经球磨机粉碎后冷压成40×9×6mm试样,冷压压力为100MPa,以10℃/min速率随炉升温,在850℃保温1h,随炉冷却。所得陶瓷宏观形貌如图7所示,其成份主要为β-Ca3(PO4)2和β-Ca2P2O7(如图8)。The stamped glass was pulverized by a ball mill and then cold-pressed into a 40×9×6mm sample with a cold-pressing pressure of 100 MPa. The temperature was raised with the furnace at a rate of 10°C/min, kept at 850°C for 1 hour, and cooled with the furnace. The macroscopic morphology of the obtained ceramics is shown in Fig. 7, and its main components are β-Ca 3 (PO 4 ) 2 and β-Ca 2 P 2 O 7 (as shown in Fig. 8 ).
实施例5Example 5
将冲压所得60CaO30P2O55Na2O3TiO22ZrO2玻璃陶瓷在模拟人体体液(表2)中37℃浸泡7天后,表面有一层致密均匀的羟基磷灰石生成。浸泡后微观形貌如图9所示。After soaking the punched 60CaO30P 2 O 5 5Na 2 O3TiO 2 2ZrO 2 glass ceramics in simulated human body fluid (Table 2) at 37°C for 7 days, a layer of dense and uniform hydroxyapatite was formed on the surface. The microscopic morphology after soaking is shown in Fig. 9.
实施例6Example 6
对冲压所得玻璃经球磨机粉碎后冷压并烧结所得陶瓷进行三点弯曲实验,测试结果显示CaO-P2O5-Na2O-TiO2-ZrO2系玻璃陶瓷的抗弯强度大于90MPa,其性能优于生物玻璃。A three-point bending test was carried out on the ceramics obtained by crushing the punched glass through a ball mill, cold pressing and sintering. The test results showed that the bending strength of the CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 series glass ceramics was greater than 90 MPa, which outperform bioglass.
实施例7Example 7
用分析纯CaCO3,Na2CO3,TiO2,ZrO2和H3PO4(液体,重量百分比为85%)为原料配制按表1所述成份玻璃浆液,用电动搅拌机将原料混合均匀,然后置于50℃干燥箱内干燥24h。将干燥后原料捣成粉末(粒度为5-10μm)置于铂金坩埚内在1300℃保温1h,立即取出倒在不锈钢钢板上并快速冲压即得玻璃。Use analytically pure CaCO 3 , Na 2 CO 3 , TiO 2 , ZrO 2 and H 3 PO 4 (liquid, 85% by weight) as raw materials to prepare a glass slurry with the ingredients described in Table 1, and mix the raw materials evenly with an electric mixer. Then place it in a drying oven at 50°C for 24 hours. Pound the dried raw material into powder (with a particle size of 5-10 μm) and place it in a platinum crucible at 1300°C for 1 hour, take it out immediately, pour it on a stainless steel plate, and press it quickly to obtain glass.
表3CaO-P2O5-Na2O-TiO2-ZrO2玻璃成份Table 3 CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 glass components
将冲压所得玻璃在37℃模拟人体体液(表2)中浸泡7天后,表面有一层致密均匀的羟基磷灰石生成,表面活性高。After soaking the stamped glass in simulated human body fluid (Table 2) at 37°C for 7 days, a layer of dense and uniform hydroxyapatite was formed on the surface with high surface activity.
将冲压所得玻璃经球磨机粉碎后用150MPa压力冷压成40×9×6mm试样,然后以10℃/min速率随炉升温,在800℃保温2h,随炉冷却。所得陶瓷宏观形貌,其成份主要为β-Ca3(PO4)2和β-Ca2P2O7。The stamped glass was pulverized by a ball mill and then cold-pressed into a 40×9×6mm sample with a pressure of 150 MPa, then heated up with the furnace at a rate of 10°C/min, kept at 800°C for 2 hours, and cooled with the furnace. The macroscopic morphology of the obtained ceramics is mainly composed of β-Ca 3 (PO 4 ) 2 and β-Ca 2 P 2 O 7 .
将冲压所得玻璃陶瓷在模拟人体体液(表2)中37℃浸泡7天后,表面有一层致密均匀的羟基磷灰石生成,其良好的生物活性和力学性质不仅可以作为牙齿、颌面骨及中耳骨亦可作为人工椎体、椎间盘和髂嵴等医用材料。After soaking the punched glass-ceramics in simulated human body fluid (Table 2) at 37°C for 7 days, a dense and uniform layer of hydroxyapatite was formed on the surface. Ear bones can also be used as medical materials such as artificial vertebral bodies, intervertebral discs and iliac crests.
实施例8Example 8
用分析纯CaCO3,Na2CO3,TiO2,ZrO2和H3PO4(液体,重量百分比为85%)为原料配制按表1所述成份玻璃浆液,用电动搅拌机将原料混合均匀,然后置于50℃干燥箱内干燥24h。将干燥后原料捣成粉末(粒度为5-10μm)置于铂金坩埚内在1400℃保温0.8h,立即取出倒在不锈钢钢板上并快速冲压即得玻璃。Use analytically pure CaCO 3 , Na 2 CO 3 , TiO 2 , ZrO 2 and H 3 PO 4 (liquid, 85% by weight) as raw materials to prepare a glass slurry with the ingredients described in Table 1, and mix the raw materials evenly with an electric mixer. Then place it in a drying oven at 50°C for 24 hours. Pound the dried raw material into powder (with a particle size of 5-10 μm) and place it in a platinum crucible at 1400°C for 0.8 hours, take it out immediately, pour it on a stainless steel plate, and press it quickly to obtain glass.
表4CaO-P2O5-Na2O-TiO2-ZrO2玻璃成份Table 4 CaO-P 2 O 5 -Na 2 O-TiO 2 -ZrO 2 glass components
将冲压所得玻璃在37℃模拟人体体液(表2)中浸泡7天后,表面有一层致密均匀的羟基磷灰石生成,表面活性高。After soaking the stamped glass in simulated human body fluid (Table 2) at 37°C for 7 days, a layer of dense and uniform hydroxyapatite was formed on the surface with high surface activity.
将冲压所得玻璃经球磨机粉碎后用80MPa压力冷压成40×9×6mm试样,然后以10℃/min速率随炉升温,在800℃保温2h,随炉冷却。所得陶瓷宏观形貌,其成份主要为β-Ca3(PO4)2和β-Ca2P2O7。The stamped glass was pulverized by a ball mill and then cold-pressed into a 40×9×6mm sample with a pressure of 80 MPa, then heated up with the furnace at a rate of 10°C/min, kept at 800°C for 2 hours, and cooled with the furnace. The macroscopic morphology of the obtained ceramics is mainly composed of β-Ca 3 (PO 4 ) 2 and β-Ca 2 P 2 O 7 .
将冲压所得玻璃陶瓷在模拟人体体液(表2)中37℃浸泡7天后,表面有一层致密均匀的羟基磷灰石生成,其良好的生物活性和力学性质不仅可以作为牙齿、颌面骨及中耳骨亦可作为人工椎体、椎间盘和髂嵴等医用材料。After soaking the punched glass-ceramics in simulated human body fluid (Table 2) at 37°C for 7 days, a dense and uniform layer of hydroxyapatite was formed on the surface. Ear bones can also be used as medical materials such as artificial vertebral bodies, intervertebral discs and iliac crests.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100472836A CN100406069C (en) | 2005-09-28 | 2005-09-28 | A kind of CaO-P2O5-Na2O-TiO2-ZrO2 biological glass ceramics and its preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100472836A CN100406069C (en) | 2005-09-28 | 2005-09-28 | A kind of CaO-P2O5-Na2O-TiO2-ZrO2 biological glass ceramics and its preparation method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1939542A CN1939542A (en) | 2007-04-04 |
CN100406069C true CN100406069C (en) | 2008-07-30 |
Family
ID=37958239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100472836A Expired - Fee Related CN100406069C (en) | 2005-09-28 | 2005-09-28 | A kind of CaO-P2O5-Na2O-TiO2-ZrO2 biological glass ceramics and its preparation method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100406069C (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101618230B (en) * | 2008-07-01 | 2013-03-27 | 叶南辉 | Method for manufacturing biomedical glass ceramic material |
CN103626396A (en) * | 2013-12-13 | 2014-03-12 | 天津工业大学 | Preparation method of titanium-containing mesoporous bioglass |
CN106630997A (en) * | 2015-03-31 | 2017-05-10 | 陈国栋 | Preparation method of composite biological ceramic for bone repair |
CN110418771B (en) * | 2017-03-16 | 2022-07-26 | 尼拉伊贾扬特·拉克加 | Preparation of porous glass and glass ceramic particle structure by gel casting |
CN109574507B (en) * | 2019-01-21 | 2022-07-05 | 河南理工大学 | Nano-scale spherical bioactive glass and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2199028A (en) * | 1986-05-21 | 1988-06-29 | Univ Sheffield | Glass ceramics |
US5196381A (en) * | 1990-01-16 | 1993-03-23 | E. I. Du Pont De Nemours And Company | Metaphosphate glass composition |
US5618763A (en) * | 1994-08-01 | 1997-04-08 | Ivoclar Ag | Alkali-zinc-silicate glass-ceramics and glasses |
US6130178A (en) * | 1998-04-16 | 2000-10-10 | Corning Incorporated | Strong miserite glass-ceramics |
-
2005
- 2005-09-28 CN CNB2005100472836A patent/CN100406069C/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2199028A (en) * | 1986-05-21 | 1988-06-29 | Univ Sheffield | Glass ceramics |
US5196381A (en) * | 1990-01-16 | 1993-03-23 | E. I. Du Pont De Nemours And Company | Metaphosphate glass composition |
US5618763A (en) * | 1994-08-01 | 1997-04-08 | Ivoclar Ag | Alkali-zinc-silicate glass-ceramics and glasses |
US6130178A (en) * | 1998-04-16 | 2000-10-10 | Corning Incorporated | Strong miserite glass-ceramics |
Also Published As
Publication number | Publication date |
---|---|
CN1939542A (en) | 2007-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2695623B1 (en) | Bioactive glass compositions, their applications and respective preparation methods | |
Kundu et al. | Doped bioactive glass materials in bone regeneration | |
CN1323986C (en) | Method for preparing CaO-P2O5-MgO glass reinforced porous beta-tricalcium phosphate bioceramics | |
Saravanapavan et al. | Binary CaO–SiO2 gel‐glasses for biomedical applications | |
WO2007124511A2 (en) | Resorbable ceramics with controlled strength loss rates | |
Ou et al. | Preparation and in vitro bioactivity of novel merwinite ceramic | |
Xie et al. | Preparation and characterization of low temperature heat-treated 45S5 bioactive glass-ceramic analogues | |
Karasu et al. | Bioactive glasses | |
JP2004249113A (en) | Bioactive rhenanite glass ceramic | |
Agathopoulos et al. | A new model formulation of the SiO2–Al2O3–B2O3–MgO–CaO–Na2O–F glass-ceramics | |
CN100406069C (en) | A kind of CaO-P2O5-Na2O-TiO2-ZrO2 biological glass ceramics and its preparation method | |
CN104548195A (en) | Mesoporous calcium magnesium silicate and polyetheretherketone composite, bone prosthesis as well as preparation method and application of composite | |
TW201000154A (en) | Method for manufacturing biomedical glassiness ceramic material | |
CN105272193B (en) | A kind of nanometer hydroxyapatite, tricalcium silicate composite boilogical ceramic and its preparation method and application | |
CN100445427C (en) | A kind of method for preparing titanium and titanium alloy glass-ceramic coating | |
Ben-Nissan et al. | Advances in bioglass and glass ceramics for biomedical applications | |
Kadhim et al. | Investigation the bioactivity of cordierite/hydroxyapatite ceramic material used in bone regeneration | |
Tahriri et al. | Bioactive glasses and calcium phosphates | |
CN106977107A (en) | One kind being capable of low sintering dentistry biological glass ceramic material and preparation method | |
Prasad et al. | Preparation, in-vitro bioactivity and mechanical properties of reinforced 45s5 bioglass composite with HA-ZRO2 powders | |
Gunduz et al. | Reinforcing of biologically derived apatite with commercial inert glass | |
Alves et al. | 3D Printing of β-TCP/S53P4 Scaffolds: Physicochemical, Mechanical, and Biological in vitro Evaluation | |
CN1754852A (en) | A machinable bioactive glass-ceramic and its preparation method | |
Owoeye et al. | Preparation and acellular in-vitro bioactivity of solid state sintered 45s5 bioactive ceramics using bio-wastes as alternative resources for biomedical applications | |
Karasu et al. | Biyoaktif Camlar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080730 Termination date: 20140928 |
|
EXPY | Termination of patent right or utility model |